Journal of Otolaryngology and Ophthalmology of Shandong University ›› 2025, Vol. 39 ›› Issue (6): 54-64.doi: 10.6040/j.issn.1673-3770.0.2024.021

• Original Article • Previous Articles    

Bibliometric analysis of biologic agents for the treatment of chronic rhinosinusitis based on the Web of Science database

LI Yangsong1,2, YUAN Fayang1,2, YANG Yan1,2, ZHANG Tian1,2, YU Guodong1,2   

  1. 1. Department of Otorhinolaryngology Head and Neck Surgery, Affiliated Hospital of Guizhou Medical University, Guiyang 550004, Guizhou, China2. Department of Clinical Medicine, Guizhou Medical University, Guiyang 550004, Guizhou, China
  • Published:2025-11-19

PDF (PC)

27

Abstract: Objective Through bibliometric analysis, this paper discussed the research status, hotspots, and development trends of biological agents in the treatment of chronic rhinosinusitis to provide a reference for research in this field. Methods Relevant literatures on the treatment of chronic rhinosinusitis with biological agents from 2004 to 2023 were retrieved from the Web of Science core collection database were retrieved. Using CiteSpace and VOSviewer software, the included literature was analyzed by country/region, institution, author, keyword, journal, and literature co-citation. Results A total of 761 articles were included, and the total number of articles was increasing. The countries, institutions and authors with the highest number of publications were the United States, Ghent University and Bachert C. The top journals in this field are International Forum of Allergy & Rhinology and Journal of Allergy And Clinical Immunology-InPractice; the research hotspots mainly focus on the application of biological agents in chronic rhinosinusitis with nasal polyps and asthma, as well as the pathophysiology of chronic rhinosinusitis; the research frontiers mainly focus on dupilumab and mepolizumab. Conclusion The curative effect of biological agents in the treatment of chronic rhinosinusitis is clear, which has gradually attracted the attention of scholars and has a good prospect of application.

Key words: Chronic rhinosinusitis, Biologics, Bibliometric, Visual analysis, Web of Science

CLC Number: 

  • R459.9
[1] 中华耳鼻咽喉头颈外科杂志编辑委员会鼻科组, 中华医学会耳鼻咽喉头颈外科学分会鼻科学组. 中国慢性鼻窦炎诊断和治疗指南(2018)[J]. 中华耳鼻咽喉头颈外科杂志, 2019, 54(2): 81-100. doi:10.3760/cma.j.issn.1673-0860.2019.02.001 Subspecialty Group of Rhinology Editorial Board of Chinese Journal of Otorhinolaryngology Head, Neck Surgery;Subspecialty Group of Rhinology Society of Otorhinolaryngology Head, NECK Surgery. Chinese guidelines for diagnosis and treatment of chronic rhinosinusitis(2018)[J]. Chinese Journal of Otorhinolaryngology Head and Neck Surgery, 2019, 54(2): 81-100. doi:10.3760/cma.j.issn.1673-0860.2019.02.001
[2] Bachert C, Bhattacharyya N, Desrosiers M, et al. Burden of disease in chronic rhinosinusitis with nasal polyps[J]. J Asthma Allergy, 2021, 14: 127-134. doi:10.2147/jaa.s290424
[3] Brzost J, Czerwaty K, D(·overz)aman K, et al. Perspectives in therapy of chronic rhinosinusitis[J]. Diagnostics(Basel), 2022, 12(10): 2301. doi:10.3390/diagnostics12102301
[4] De Corso E, Settimi S, Montuori C, et al. How to manage recurrences after surgery in CRSwNP patients in the biologic era: a narrative review[J]. Acta Otorhinolaryngol Ital, 2023, 43(suppl. 1): S3-S13. doi:10.14639/0392-100x-suppl.1-43-2023-01
[5] 石帅, 郑泉. 度普利尤单抗在慢性鼻窦炎伴鼻息肉治疗中的研究进展[J]. 山东大学耳鼻喉眼学报, 2022, 36(3): 36-42. doi:10.6040/j.issn.1673-3770.0.2021.565 SHI Shuai, ZHENG Quan. Research advances of dupilumab in the treatment of chronic rhinosinusitis with nasal polyps[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 36-42. doi:10.6040/j.issn.1673-3770.0.2021.565
[6] Fokkens WJ, Lund VJ, Hopkins C, et al. European position paper on rhinosinusitis and nasal polyps 2020[J]. Rhinology, 2020, 58(suppl s29): 1-464. doi:10.4193/rhin20.600
[7] Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps(liberty np sinus-24 and liberty np sinus-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials[J]. Lancet, 2019, 394(10209): 1638-1650. doi:10.1016/s0140-6736(19)31881-1
[8] Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial[J]. JAMA, 2016, 315(5): 469-479. doi:10.1001/jama.2015.19330
[9] Noone PG, Leigh MW, Sannuti A, et al. Primary ciliary dyskinesia: diagnostic and phenotypic features[J]. Am J Respir Crit Care Med, 2004, 169(4): 459-467. doi:10.1164/rccm.200303-365oc
[10] Akdis CA, Bachert C, Cingi C, et al. Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology[J]. J Allergy Clin Immunol, 2013, 131(6): 1479-1490. doi:10.1016/j.jaci.2013.02.036
[11] Pires A, Fortuna A, Alves G, et al. Intranasal drug delivery: how, why and what for?[J]. J Pharm Pharm Sci, 2009, 12(3): 288-311. doi:10.18433/j3nc79
[12] Bal SM, Bernink JH, Nagasawa M, et al. IL-1β, IL-4 and IL-12 control the fate of group 2 innate lymphoid cells in human airway inflammation in the lungs[J]. Nat Immunol, 2016, 17: 636-645. doi:10.1038/ni.3444
[13] Gevaert P, Lang-Loidolt D, Lackner A, et al. Nasal IL-5 levels determine the response to anti–IL-5 treatment in patients with nasal polyps[J]. J Allergy Clin Immunol, 2006, 118(5): 1133-1141. doi:10.1016/j.jaci.2006.05.031
[14] Schleimer RP. Immunopathogenesis of chronic rhinosinusitis and nasal polyposis[J]. Annu Rev Pathol, 2017, 12: 331-357. doi:10.1146/annurev-pathol-052016-100401
[15] Ordovas-Montanes J, Dwyer DF, Nyquist SK, et al. Allergic inflammatory memory in human respiratory epithelial progenitor cells[J]. Nature, 2018, 560: 649-654. doi:10.1038/s41586-018-0449-8
[16] Dougherty RH, Fahy JV. Acute exacerbations of asthma: epidemiology, biology and the exacerbation-prone phenotype[J]. Clin Exp Allergy, 2009, 39(2): 193-202. doi:10.1111/j.1365-2222.2008.03157.x
[17] 李华斌, 赖玉婷. 慢性鼻-鼻窦炎的发病机制及诊疗进展[J]. 山东大学耳鼻喉眼学报, 2018, 4(3): 4-9. doi:10.6040/j.issn.1673-3770.1.2018.004 LI Huabin, LAI Yuting. Pathogenesis, diagnosis, and treatment of chronic rhinosinusitis[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2018, 4(3): 4-9. doi:10.6040/j.issn.1673-3770.1.2018.004
[18] de Benedictis FM, Bush A. Janus looks both ways: how do the upper and lower airways interact?[J]. Paediatr Respir Rev, 2020, 34: 59-66. doi:10.1016/j.prrv.2019.06.004
[19] König IR, Fuchs O, Hansen G, et al. What is precision medicine?[J]. Eur Respir J, 2017, 50(4): 1700391. doi:10.1183/13993003.00391-2017
[20] Tai J, Han M, Kim TH. Therapeutic strategies of biologics in chronic rhinosinusitis: current options and future targets[J]. Int J Mol Sci, 2022, 23(10): 5523. doi:10.3390/ijms23105523
[21] Thamboo A, Kilty S, Witterick I, et al. Canadian Rhinology Working Group consensus statement: biologic therapies for chronic rhinosinusitis[J]. J Otolaryngol Head Neck Surg, 2021, 50(1): 15. doi:10.1186/s40463-021-00493-2
[22] Zhang Y, Gevaert E, Lou HF, et al. Chronic rhinosinusitis in Asia[J]. J Allergy Clin Immunol, 2017, 140(5): 1230-1239. doi:10.1016/j.jaci.2017.09.009
[23] Laidlaw TM, Mullol J, Woessner KM, et al. Chronic rhinosinusitis with nasal polyps and asthma[J]. J Allergy Clin Immunol Pract, 2021, 9(3): 1133-1141. doi:10.1016/j.jaip.2020.09.063
[24] Laidlaw TM, Buchheit KM. Biologics in chronic rhinosinusitis with nasal polyposis[J]. Ann Allergy Asthma Immunol, 2020, 124(4): 326-332. doi:10.1016/j.anai.2019.12.001
[25] Bachert C, Han JK, Wagenmann M, et al. EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps(CRSwNP)and biologics: Definitions and management[J]. J Allergy Clin Immunol, 2021, 147(1): 29-36. doi:10.1016/j.jaci.2020.11.013
[26] Gevaert P, Saenz R, Corren J, et al. Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study[J]. J Allergy Clin Immunol, 2022, 149(3): 957-965. doi:10.1016/j.jaci.2021.07.045
[27] Roland LT, Smith TL, Schlosser RJ, et al. Guidance for contemporary use of biologics in management of chronic rhinosinusitis with nasal polyps: discussion from a National Institutes of Health-sponsored workshop[J]. Int Forum Allergy Rhinol, 2020, 10(9): 1037-1042. doi:10.1002/alr.22633
[28] Brown WC, Senior B. A critical look at the efficacy and costs of biologic therapy for chronic rhinosinusitis with nasal polyposis[J]. Curr Allergy Asthma Rep, 2020, 20(6): 16. doi:10.1007/s11882-020-00910-y
[29] 王成硕, 张罗. 慢性鼻窦炎伴鼻息肉进入生物制剂治疗时代[J]. 中华耳鼻咽喉头颈外科杂志, 2021, 56(10): 1023-1027. doi:10.3760/cma.j.cn115330-20210509-00260 WANG Chengshuo, ZHANG Luo. Biologics: a new option in treatment of chronic rhinosinusitis with nasal polyps[J]. Chinese Journal of Otorhinolaryngology Head and Neck Surgery, 2021, 56(10): 1023-1027. doi:10.3760/cma.j.cn115330-20210509-00260
[30] Fokkens WJ, Lund V, Bachert C, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma[J]. Allergy, 2019, 74(12): 2312-2319. doi:10.1111/all.13875
[31] 崇维琨, 王娟. 联合应用奥马珠单抗在儿童中重度变应性哮喘合并慢性鼻窦炎中的疗效观察[J]. 山东大学耳鼻喉眼学报, 2024, 38(1): 21-26. doi:10.6040/j.issn.1673-3770.0.2022.544 CHONG Weikun, WANG Juan. Efficacy of Omalizumab in children with moderate and severe allergic asthma and chronic sinusitis[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2024, 38(1): 21-26. doi:10.6040/j.issn.1673-3770.0.2022.544
[32] Rizzi A, Gammeri L, Cordiano R, et al. Therapeutic strategies to prevent the recurrence of nasal polyps after surgical treatment: an update and in vitro study on growth inhibition of fibroblasts[J]. J Clin Med, 2023, 12(8): 2841. doi:10.3390/jcm12082841
[33] Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial[J]. Lancet, 2023, 401(10371): 105-117. doi:10.1016/s0140-6736(22)02420-5
[1] ZHANG Jiaqi, YUAN Ye, HONG Chen, GU Min, CHENG Lei, LU Meiping. Mendelian randomization study of gut microbiota, chronic sinusitis, and nasal polyps: Causal relationships and metabolite-mediated effects [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(5): 49-60.
[2] ZHANG Guangling, CHEN Xingxue, WU Tianyi, SUN Zhanwei, WANG Weiwei, LI Shichao,WANG Guangke. The expression and function of Tespa1 in chronic rhinosinusitis with nasal polyps [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(2): 35-42.
[3] CAO Zhengyong, LI Xiaobo. Comparison of the safety and efficacy of short-course postoperative topical glucocorticoid adjuvant therapy for eCRSwNP combined with asthma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(2): 43-50.
[4] WANG Aowei, SHI Wenjie. Study on correlation between traditional Chinese medicine syndrome types and TFH cell related factors in CRSwNP [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(1): 54-60.
[5] ZHANG Jie, NIMA Jizong, XU Xiaodong, ZHOU Jing, LIU Jianmin, LUO Yirui, DU Jintao, BA Luo. Effect of Crocin on Type 2 inflammation in eosinophilic chronic rhinosinusitis with nasal polyps [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(1): 61-67.
[6] LI Ting, ZHAO Chong, WU Xian. The relationship between miR-34a expression in nasal mucosa tissue and postoperative recurrence in patients with chronic sinusitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2024, 38(5): 20-25.
[7] CHEN Xingxue, ZHANG Guangling, WU Tianyi, WANG Weiwei, SUN Zhanwei, LI Shichao, WANG Guangke. Analysis of anti-IL-4Rα monoclonal antibody and endoscopic sinus surgery in the treatment of eosinophilic chronic rhinosinusitis with nasal polyps [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2024, 38(4): 43-54.
[8] ZHANG Shihan, LIU Hongbing. Effect of matrix metalloproteinase on tissue remodeling in chronic rhinosinusitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2024, 38(3): 116-123.
[9] LI Xia, HOU Ran, WANG Liping. Bibliometric analysis based on Web of Science for nasal irrigation for nasal diseases in the last decade [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2024, 38(2): 52-60.
[10] WANG Jiahui, LIU Xueqin. A global study on quality of life related to dry eye in the last ten years: bibliometrics and visualization analysis through VOSviewer and CiteSpace [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2024, 38(2): 61-72.
[11] WANG Xiaoai, ZHANG Qianqian, CHENG Xiangyu, LI Zhipeng, ZHANG Weitian, YE Haibo. A clinical efficacy analysis of vidian neurectomy in the treatment of type 2 chronic rhinosinusitis with allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(5): 42-49.
[12] ZHU Yu, ZHU Xinhua. Research progress on the role of TH2 cytokines in Type2 chronic rhinosinusitis with nasal polyps [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(5): 156-161.
[13] LI Dan, CHEN Tengyu, HUANG Yanfen, ZHOU Min, ZHOU Yixing, RUAN Yan, YAN Yajie. Research in the field of olfactory disorders in China—An analysis based on Citespace [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(4): 40-48.
[14] AO Tian,CHENG Lei. An endotype study of chronic rhinosinusitis with nasal polyps and precise control and treatment under the guidance [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 7-14.
[15] YAO Shuang,LOU Hongfei. Advances in endotypes and precision medicine in chronic rhinosinusitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 20-29.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Website Copyright: Editorial Office of Journal of Otolaryngology and Ophthalmology of Shandong University
Address: No.27 Shanda South Road, Jinan, Shandong, China. Post code: 250100 Tel: +86-0531-88366912 Email: ebhxb@sdu.edu.cn Supported by Beijing Magtech Co.Ltd